Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Diabetic Retinopathy Market Forecast and it is segmented by Type (Proliferative diabetic retinopathy, Non-proliferative retinopathy), Management Approach (Anti-VEGF Drug, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy) and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The Values are Provided in Terms of USD Million for above segments.

Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Diabetic Retinopathy Market Size

Diabetic Retinopathy Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 11.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Diabetic Retinopathy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Diabetic Retinopathy Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Diabetic Retinopathy Market Analysis

The Global Diabetic Retinopathy Market is expected to register a CAGR of 11.5% during the forecast period.

The COVID-19 pandemic led to disruption in not only the research and development activities of other therapies and drugs for medical conditions other than COVID-19 but also impacted the treatment procedures and supply chain of the pharmaceuticals and medical devices around the world which also impacted the studied market of diabetic retinopathy. However, lockdown led to the sudden transition to online activities which not only involved work but also education and entertainment and this led to increase in the screen time of individuals along with usage of vision correction devices such as contact lenses and spectacles. Further, the COVID-19 pandemic is expected to have a long-term impact on the people as today also a significant number of daily activities are being performed online which may have a negative impact on the eyes and led to increase in the demand for vision correction drugs and devices, thus positively impacting the market.

Certain factors that are driving the market growth include the rising prevalence of diabetes and blindness due to the same, growing geriatric population base, increasing technological advancements in diabetic retinopathy surgical instruments.

Diabetic retinopathy (DR) is a leading cause of vision-loss globally. The most clinically important risk factors for progression to vision loss include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. There is an increasing burden of diabetic retinopathy across the globe. The increasing burden of diabetes is also driving the growth of market. As per "Diabetic retinopathy screening: a short guide" published by World health Organization in 2020, the prevalence of any retinopathy in persons with diabetes is 35% while proliferative (vision-threatening) retinopathy is 7%. Additionally, the International Diabetes Federation Diabetes Atlas, 10th edition 2021 reported that in 2021, globally there are about 536,600,000 people with diabetes, and it is estimated to reach 783,700,000 by the year 2045. such growing burden of diabetes rises the risk of diabetes retinopathy and thus, expected to drive the growth of market.

Additionally, the services launched for the diagnosis and improvement in diagnosis is also driving the growth of market in the country. For Instance, in December 2021, Eyenuk, Inc in collaboration with Discovery Health has launched a new Diabetic Retinopathy Screening Benefit nationwide in South Africa, powered by the cutting-edge EyeArt Artificial Intelligent System. It helps in enabling the detection of the onset of diabetic retinopathy as early as possible. Such benefits plans and services increases the early detection of the diseases and hence drives the growth of market.

According to the research study published in May 2021, titled 'A deep learning system for detecting diabetic retinopathy across the disease spectrum', the screening of retina can help in the early detection of the diabetic retinopathy which can be used for administering the timely treatment, and as per the study, the DeepDR system achieved high sensitivity and specificity in diabetic retinopathy grading and with the introduction of the image quality sub-network and lesion-aware sub-network into DeepDR, it improved the diagnostic performance and more closely followed the thought process of ophthalmologists. Thus, the DeepDR has great potential to improve the accessibility and efficiency of diabetic retinopathy screening which may be incorporated in the future devices and drive the growth in the studied market.

Hence, the rising prevalence of diabetic retinopathy, along with the growing awareness and concern over it, are expected to drive the market growth over the forecast period. however, lack of skilled ophthalmologists and extended time for product approvals are expected to hinder the market.

Diabetic Retinopathy Industry Overview

The Diabetic Retinopathy market is moderately competitive and consists of a few major players. Companies like Alimera Sciences, Allergan plc, BCN Peptides, F. Hoffmann-La Roche Ltd, Glycadia Pharmaceuticals, Kowa Group, Novartis AG, and Oxurion NV. The players are adopting strategies such as partnerships and acquisitions, product launches, research and development activities, and rising investments to strengthen their presence in the market.

Diabetic Retinopathy Market Leaders

  1. Regeneron Pharmaceuticals, Inc.

  2. Alimera Sciences

  3. Oxurion NV.

  4. Abbvie Inc.

  5. F. Hoffmann-La Roche Ltd

  6. *Disclaimer: Major Players sorted in no particular order
Diabetic Retinopathy Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Diabetic Retinopathy Market News

  • In June 2022, Regeneron Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR).
  • In February 2022, REGENXBIO Inc. announced additional positive interim data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.

Diabetic Retinopathy Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Diabetes and Blindness Due to The Same
    • 4.2.2 Growing Geriatric Population Base
    • 4.2.3 Increasing Technological Advancements in Diabetic Retinopathy Surgical Instruments
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Ophthalmologists
    • 4.3.2 Extended Approval Time for Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market SIze by Value - in USD Million)

  • 5.1 By Type
    • 5.1.1 Proliferative Diabetic Retinopathy
    • 5.1.2 Non-proliferative Retinopathy
  • 5.2 By Management Approach
    • 5.2.1 Anti-VEGF Drug
    • 5.2.2 Intraocular Steroid Injection
    • 5.2.3 Laser Surgery
    • 5.2.4 Vitrectomy
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Alimera Sciences
    • 6.1.2 AbbVie Inc. (Allergan plc)
    • 6.1.3 BCN Peptides
    • 6.1.4 F. Hoffmann-La Roche Ltd (Genentech)
    • 6.1.5 Glycadia Pharmaceuticals
    • 6.1.6 Ocuphire Pharma
    • 6.1.7 Novartis AG
    • 6.1.8 Regeneron Pharmaceuticals Inc
    • 6.1.9 Oxurion NV.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Diabetic Retinopathy Industry Segmentation

As per the scope of the report, diabetic retinopathy refers to a diabetes complication that affects eyes, DR results in damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Initially, diabetic retinopathy may cause no symptoms or only mild vision problems. But eventually, it can cause blindness. The Diabetic Retinopathy Market is segmented by Type (Proliferative diabetic retinopathy, Non-proliferative retinopathy), Management Approach (Anti-VEGF Drug, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy) and Geography (North America, Europe, Asia - Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type Proliferative Diabetic Retinopathy
Non-proliferative Retinopathy
By Management Approach Anti-VEGF Drug
Intraocular Steroid Injection
Laser Surgery
Vitrectomy
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Diabetic Retinopathy Market Research FAQs

What is the current Global Diabetic Retinopathy Market size?

The Global Diabetic Retinopathy Market is projected to register a CAGR of 11.5% during the forecast period (2025-2030)

Who are the key players in Global Diabetic Retinopathy Market?

Regeneron Pharmaceuticals, Inc., Alimera Sciences, Oxurion NV., Abbvie Inc. and F. Hoffmann-La Roche Ltd are the major companies operating in the Global Diabetic Retinopathy Market.

Which is the fastest growing region in Global Diabetic Retinopathy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Diabetic Retinopathy Market?

In 2025, the North America accounts for the largest market share in Global Diabetic Retinopathy Market.

What years does this Global Diabetic Retinopathy Market cover?

The report covers the Global Diabetic Retinopathy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Diabetic Retinopathy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Diabetic Retinopathy Industry Report

Statistics for the 2025 Global Diabetic Retinopathy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Diabetic Retinopathy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Diabetic Retinopathy Market Report Snapshots